Anti-CD19 CAR T cell therapy for refractory SLE-ITP

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Systemic lupus erythematosus (SLE) with immune thrombocytopenia (ITP) presents significant bleeding risks and poor survival rates.
• Conventional and biologic therapies offer limited efficacy for SLE-ITP patients.
• Refractory SLE-ITP necessitates novel therapeutic approaches.

Purpose of the Study:

• To evaluate the safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T cell therapy in patients with refractory SLE-ITP.
• To assess clinical response rates, including complete remission (CR) and partial remission (PR).

Main Methods:

• A single-arm, dose-escalation trial involving six patients with refractory SLE-ITP.
• Patients received anti-CD19 CAR T cells following lymphodepleting chemotherapy.
• Safety and overall response rate were primary and secondary outcomes, respectively.

Main Results:

• All six patients achieved a clinical response (CR or PR), with three reaching CR.
• No severe adverse events like immune effector cell-associated neurotoxicity syndrome (ICANS) were observed.
• Exploratory multi-omics revealed insights into B cell signaling and megakaryocyte maturation pathways in responders.

Conclusions:

• Anti-CD19 CAR T cell therapy is a potentially safe and effective treatment for refractory SLE-ITP.
• Further large-scale clinical trials are required to validate these preliminary findings.
• This therapy offers a promising new avenue for managing this challenging autoimmune condition.